FGF19 and hepatocellular carcinoma: Importantly, an inhibitor of FGFR4, Fisogatinib (BLU-554), has demonstrated clinical activity in HCC patients with aberrant FGF19 expression (Kim et al, 2019) (phase I clinical trial, NCT02508467).